Jon D Piganelli
Overview
Explore the profile of Jon D Piganelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
2589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Austin M, Muralidharan C, Roy S, Crowder J, Piganelli J, Linnemann A
Front Immunol
. 2025 Feb;
16:1504583.
PMID: 39944686
Background: Type 1 Diabetes (T1D) is caused by a combination of genetic and environmental factors that trigger autoimmune-mediated destruction of pancreatic β-cells. Defects in β-cell stress response pathways such as...
2.
Rao C, Cater D, Roy S, Xu J, De Oliveira A, Evans-Molina C, et al.
Diabetologia
. 2024 Nov;
68(2):382-396.
PMID: 39508879
Aims/hypothesis: Surviving beta cells in type 1 diabetes respond to inflammation by upregulating programmed death-ligand 1 (PD-L1) to engage immune cell programmed death protein 1 (PD-1) and limit destruction by...
3.
Rao C, Cater D, Roy S, Xu J, Olivera A, Evans-Molina C, et al.
bioRxiv
. 2024 Sep;
PMID: 39345410
Aims/hypothesis: Surviving beta cells in type 1 diabetes respond to inflammation by upregulating programmed death-ligand 1 (PD-L1) to engage immune cell programmed death-1 (PD-1) and limit destruction by self-reactive immune...
4.
Roy S, Pokharel P, Piganelli J
Mol Metab
. 2024 Jul;
88:101998.
PMID: 39069156
Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by the specific destruction of insulin-producing beta cells in the pancreas by the immune system, including CD4 cells which orchestrate...
5.
Dahiya S, Saleh M, Rodriguez U, Rajasundaram D, R Arbujas J, Hajihassani A, et al.
Nat Commun
. 2024 May;
15(1):3740.
PMID: 38702347
Insufficient functional β-cell mass causes diabetes; however, an effective cell replacement therapy for curing diabetes is currently not available. Reprogramming of acinar cells toward functional insulin-producing cells would offer an...
6.
Sugitani N, Mason H, Campfield B, Piganelli J
Front Immunol
. 2024 Jan;
14:1290058.
PMID: 38164129
Type 1 diabetes (T1D) affects three million Americans, with 80 new people diagnosed each day. T1D is currently uncurable and there is an urgent need to develop additional drug candidates...
7.
Epithelial NAD depletion drives mitochondrial dysfunction and contributes to intestinal inflammation
Novak E, Crawford E, Mentrup H, Griffith B, Fletcher D, Flanagan M, et al.
Front Immunol
. 2023 Sep;
14:1231700.
PMID: 37744380
Introduction: We have previously demonstrated that a pathologic downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1α) within the intestinal epithelium contributes to the pathogenesis of inflammatory bowel disease (IBD). However,...
8.
Rodriguez U, Dahiya S, Raymond M, Gao C, Martins-Cargill C, Piganelli J, et al.
Development
. 2022 Aug;
149(17).
PMID: 36017799
Signals from the endothelium play a pivotal role in pancreatic lineage commitment. As such, the fate of the epithelial cells relies heavily on the spatiotemporal recruitment of the endothelial cells...
9.
Green E, Cooke A, Piganelli J, Richardson S, Wen L, Wong F
Front Immunol
. 2022 Apr;
13:852963.
PMID: 35359940
No abstract available.
10.
Martins C, New L, OConnor E, Previte D, Cargill K, Tse I, et al.
Front Immunol
. 2021 Jun;
12:669456.
PMID: 34163475
In Type 1 Diabetes (T1D), CD4 T cells initiate autoimmune attack of pancreatic islet β cells. Importantly, bioenergetic programs dictate T cell function, with specific pathways required for progression through...